No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on limited data for metabolism and clearance a clinically significant interaction is unlikely, although due to the lack of data, vigilance is required if administering melarsoprol with antiretrovirals. It is unknown whether urinary metabolites of melarsoprol, such as arsenic, are excreted via active renal mechanisms, however a clinical study has reported that urinary pharmacokinetic parameters are not predictive of toxicity or therapeutic efficacy. Therefore emtricitabine and tenofovir have little potential to effect melarsoprol treatment via competition for renal elimination mechanisms.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking